The company continues to witness strong contributions from key areas like Population Health, Revenue Cycle and IT Works.The same for EPS stands at a loss of 60 cents, indicating growth of 9.1% from the prior-year quarter.The Zacks Consensus Estimate for ViewRay’s first-quarter 2020 earnings per share stands at a loss of 20 cents, suggesting an improvement of 41.8% from the year-ago period.The Zacks Consensus Estimate for ResMed’s third-quarter fiscal 2020 revenues is pegged at $715.6 million, suggesting year-over-year improvement of 8.1%.